Low-dose oral minoxidil beyond androgenetic alopecia: A comparative review of emerging evidence

Low-dose oral minoxidil (LDOM) has emerged as an off-label therapy for various forms of hair loss. Originally developed as an antihypertensive, minoxidil gained dermatologic relevance because systemic use was associated with hypertrichosis. Topical minoxidil is approved for androgenetic alopecia, yet adherence can be poor due to scalp irritation, messy application and cosmetic constraints. Oral minoxidil offers convenient dosing but raises safety concerns. This review synthesizes evidence from peer-reviewed studies and case series to evaluate LDOM beyond androgenetic alopecia. Mechanisms, dosing, efficacy, and safety are summarized. Available evidence suggests that LDOM may improve hair density, follicle density, photographic response, or shedding in selected nonandrogenetic alopecias, particularly chronic telogen effluvium and treatment-related alopecia, whereas support for alopecia areata, scarring alopecias, and rare hair-cycle or hair-shaft disorders remains limited and largely based on retrospective studies, case series, or case reports. Hypertrichosis is the most common adverse effect, whereas serious cardiovascular complications are rare but reported. Across indications, the quality of evidence is heterogeneous, and in several conditions, LDOM appears more useful as a symptomatic or density-enhancing adjunct than as a clearly disease-modifying therapy. Current evidence is mainly retrospective and uncontrolled; prospective randomized trials and long-term safety studies are needed.